Honma S, Takezawa Y, Yamanaka H
Pharmacokinetics Research Department, Teikoku Hormone Mfg. Co. LTD, Kawasaki, Japan.
Nihon Naibunpi Gakkai Zasshi. 1995 Jul 20;71(5):679-94. doi: 10.1507/endocrine1927.71.5_679.
TZP-4238 suppresses plasma testosterone in humans, but its action on the androgen biosynthesis pathway has not been established. Therefore, we researched the testicular testosterone level and the testosterone biosynthesis pathway in vitro in rats before and after receiving a single or continuous oral dose of TZP-4238. The total testosterone fell to 60% of the basal level within 3-8 hr (p < 0.05) and then returned to the control concentration by 24 hr after a single administration of 32 mg/kg. The alteration of the plasma testosterone level correlated well with that of the intratesticular level, which was decreased to 50% at 3-8 hr and recovered to the control level by 24 hr. However, the decrement of the plasma LH level at 3-8 hr after a single oral administration was slight and it then returned to the original level at 12 hr. During the 8 weeks of daily administration of 0.5 mg/kg of TZP-4238 or chlormadinone acetate to dogs, the plasma testosterone levels were slightly lower than the basal extent. In vitro experiments were conducted on the rat testis using the exogenous precursor steroids 20 alpha-hydroxycholesterol, pregnenolone and progesterone, in various steps leading to the biosynthesis of testosterone. Trilostane acted at 3 beta-hydroxysteroid dehydrogenase (50% inhibition concentration, IC50 was 1 microM), ketoconazole inhibited the 17 alpha-hydroxylase, and C20, 22- and C17, 20-lyase activities, with an IC50 of 1-50 microM. Cyproterone acetate inhibited both the 3 beta-hydroxysteroid dehydrogenase (IC50;50 microM) and C17, 20-lyase. On the other hand, TZP-4238 exhibited a weaker inhibition of 3 beta-hydroxysteroid dehydrogenase (IC50; 100 microM) than cyproterone acetate, but not of hydroxylase and lyase. Though TZP-4238 did not inhibit the increased testosterone level induced by hCG, trilostane markedly inhibited the effect induced by hCG.(ABSTRACT TRUNCATED AT 250 WORDS)
TZP - 4238可抑制人体血浆睾酮水平,但其对雄激素生物合成途径的作用尚未明确。因此,我们研究了大鼠单次或连续口服TZP - 4238前后睾丸睾酮水平及体外睾酮生物合成途径。单次给予32 mg/kg后,总睾酮在3 - 8小时内降至基础水平的60%(p < 0.05),然后在24小时后恢复至对照浓度。血浆睾酮水平的变化与睾丸内水平变化密切相关,睾丸内睾酮水平在3 - 8小时降至50%,并在24小时恢复至对照水平。然而,单次口服后3 - 8小时血浆促黄体生成素(LH)水平略有下降,随后在12小时恢复至原始水平。在给犬每日口服0.5 mg/kg的TZP - 4238或醋酸氯地孕酮8周期间,血浆睾酮水平略低于基础水平。利用外源性前体类固醇20α - 羟基胆固醇、孕烯醇酮和孕酮,在导致睾酮生物合成的各个步骤中对大鼠睾丸进行了体外实验。曲洛司坦作用于3β - 羟基类固醇脱氢酶(50%抑制浓度,IC50为1 μM),酮康唑抑制17α - 羟化酶以及C20、22 - 和C17、20 - 裂解酶活性,IC50为1 - 50 μM。醋酸环丙孕酮抑制3β - 羟基类固醇脱氢酶(IC50;50 μM)和C17、20 - 裂解酶。另一方面,TZP - 4238对3β - 羟基类固醇脱氢酶的抑制作用(IC50;100 μM)比醋酸环丙孕酮弱,对羟化酶和裂解酶无抑制作用。虽然TZP - 4238不抑制人绒毛膜促性腺激素(hCG)诱导的睾酮水平升高,但曲洛司坦显著抑制hCG诱导的效应。(摘要截短于250字)